Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

NVAX

Financials

Novavax Inc

Noticias

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Las acciones de Novavax suben mientras activista impulsa cambios en la junta

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Routine Vaccines Okay For Now: Investment Implications Of The Court Decision (XLV)

Jefferies reitera compra en acciones de Novavax, cita plataforma adyuvante

Jefferies reitera Compra en Novavax; destaca plataforma de adyuvantes

Jefferies reiterates Buy on Novavax stock, cites adjuvant platform

Novavax en la Conferencia Global de Salud de Leerink: Cambio Estratégico

Novavax en Conferencia Global de Salud Leerink: Cambio Estratégico

Novavax at Leerink Global Healthcare Conference: Strategic Shift in Focus

Novavax en la Conferencia de TD Cowen: Cambio estratégico hacia licencias de adyuvante